Holly Lin

Holly Lin has a diverse and extensive work experience in the pharmaceutical and biotechnology industry. Holly currently serves as the Director of Biomarker Operations at Annexon Biosciences. Prior to that, they worked at BeiGene as an Associate Director of Biomarker Operations, where they led a group responsible for executing biomarker operations activities and implementing biomarker strategies.

Before their role at BeiGene, Holly worked at Nektar Therapeutics as the Director of Biosample Management, where they oversaw the overall operations of the clinical sample management group and implemented a streamlined process across internal and external stakeholders.

Holly'sprevious experience includes working at Gilead Sciences as a Clinical Program Manager in Biomarker Operations, and at Elan Pharmaceuticals in various roles including Senior Manager of Bioanalytics, Principal Scientist/Staff Scientist in Technical Operations, and Scientist in Technical Operations.

Overall, Holly Lin has demonstrated expertise in biomarker operations, clinical sample management, and technical operations within the pharmaceutical and biotechnology industry.

Holly Lin has a Bachelor of Science (BS) degree in Biomedical/Medical Engineering from Zhejiang University. Holly also holds a Master of Science (MS) degree and a Doctor of Philosophy (PhD) degree in Biology, both from The University of British Columbia.